Generic Sector Forecast Upgraded
July 2007 | Industry ForecastBMI has marginally upgraded its projection for Japan's generic drug market after a basket of medicines lost patent protection and public knowledge of the benefit of this type of pharmaceutical improved. Moreover, the spread of flat-sum reimbursement schemes, a number of fee changes and increased co-payments for drugs over the past few years have also had an effect. A key change in 2006 was the introduction of a tick box on script forms, allowing doctors to indicate their approval of substitution. We fully expect the uptake of generics in Japan to continue, with the value of the sub-sector reaching US$9.44bn
Sorry, you must be a subscriber to view this article in full. If you are a subscriber please login.
If you would like to subscribe to Asia Pacific Pharma & Healthcare Insight and gain instant access to this article, please click here to subscribe.
If you would like to take a trial to Asia Pacific Pharma & Healthcare Insight please click on the trial link below.
